To investigate the effect of thyroid dysfunction on high-density lipoprotein (HDL) metabolism, we measured HDL subfractions, apolipoprotein A-I containing particles (LpA-I and LpA-I:A-II), and the activities of enzymes involved in the remodeling and metabolism of HDL [namely hepatic lipase (HL), lipoprotein lipase, and cholesteryl ester transfer protein (CETP)] in 18 hyperthyroid and 17 hypothyroid patients before and after treatment. HDL was subfractionated by density gradient ultracentrifugation, and LpA-I was analyzed by electroimmunodiffusion. The major changes were found in the HDL 2 subfraction and in LpA-I particles. HDL 2 -C and LpA-I were reduced in hyperthyroidism (P Ͻ 0.01, P Ͻ 0.05, respectively) and increased in hypothyroidism (both P Ͻ 0.05) compared with their respective euthyroid matched controls. Changes in HDL 2 -cholesterol were reversed after treatment in both hyper-and hypothyroid patients, and LpA-I also decreased in the hypothyroid patients after treatment. HL (P Ͻ 0.05) and CETP activities (P Ͻ 0.05) were elevated in hyperthyroidism and reduced in hypothyroidism (P Ͻ 0.05, P Ͻ 0.01 respectively) and both were related to free T 4 levels. The changes in HDL 2 -C and LpA-I correlated significantly with changes in HL after treatment but not with CETP or lipoprotein lipase. In summary, HDL metabolism was altered in thyroid dysfunction, and the effect of thyroid hormone on HDL was mediated mainly via its effect on HL activity. (J Clin Endocrinol Metab 83: [2921][2922][2923][2924] 1998) T HE EFFECT of thyroid dysfunction on low-density lipoprotein (LDL) metabolism is well described in the literature. Thyroid hormone has been shown to modulate LDL receptor activity, thus leading to changes in plasma LDL levels, which are reversible on treatment of the underlying thyroid disorder. However, the effect of thyroid dysfunction on high-density lipoprotein (HDL) metabolism is less well understood. HDL cholesterol has been reported to be normal (1) or decreased (2, 3) in hyperthyroidism, whereas in hypothyroidism, HDL has been reported to be increased (3-5), normal (6), or even decreased (7). Apolipoprotein (apo) A-I level tends to mirror the changes in HDL cholesterol. Limited information is available on the effects of thyroid dysfunction on the distribution of HDL subfractions and their metabolism. There is only one published study that examined HDL subfractions in hyperthyroidism. Muls et al. (2) reported that the concentration of HDL 2b is decreased in hyperthyroid patients. In hypothyroidism, several studies have examined the effect of T 4 replacement therapy on HDL subfractions (4, 6, 8, 9) . HDL 2 decreased after treatment, and the changes in HDL subfractions are thought to be mediated by the effect of thyroid hormone on hepatic lipase (HL) (8).
T HE EFFECT of thyroid dysfunction on low-density lipoprotein (LDL) metabolism is well described in the literature. Thyroid hormone has been shown to modulate LDL receptor activity, thus leading to changes in plasma LDL levels, which are reversible on treatment of the underlying thyroid disorder. However, the effect of thyroid dysfunction on high-density lipoprotein (HDL) metabolism is less well understood. HDL cholesterol has been reported to be normal (1) or decreased (2, 3) in hyperthyroidism, whereas in hypothyroidism, HDL has been reported to be increased (3) (4) (5) , normal (6) , or even decreased (7) . Apolipoprotein (apo) A-I level tends to mirror the changes in HDL cholesterol. Limited information is available on the effects of thyroid dysfunction on the distribution of HDL subfractions and their metabolism. There is only one published study that examined HDL subfractions in hyperthyroidism. Muls et al. (2) reported that the concentration of HDL 2b is decreased in hyperthyroid patients. In hypothyroidism, several studies have examined the effect of T 4 replacement therapy on HDL subfractions (4, 6, 8, 9) . HDL 2 decreased after treatment, and the changes in HDL subfractions are thought to be mediated by the effect of thyroid hormone on hepatic lipase (HL) (8) .
We have recently shown that plasma cholesteryl ester transfer protein (CETP) is increased in patients with hyperthyroidism and reduced in those with hypothyroidism compared with their respective matched euthyroid controls (10) .
CETP is a hydrophobic glycoprotein that mediates the transfer of neutral lipids between lipoproteins and plays an important role in the metabolism of HDL and apo A-I and in the reverse cholesterol transport pathway (11) . The aim of the present study was to investigate the relative roles of CETP and HL in the metabolism of HDL subfractions in patients with thyroid dysfunction. We had documented HDL subfractions and apo A-I-containing particles (LpA-I and LpA-I:A-II) in the cohort of patients described in our previous study (10) , and determined whether the changes in HDL subfractions were related to changes in the activities of plasma lipolytic enzymes and/or CETP.
Patients and Methods
Patients with thyroid dysfunction were recruited from the Thyroid Clinic of the University of Hong Kong. Eighteen female patients with active Graves' disease and 17 patients (3 males and 14 females) with newly diagnosed hypothyroidism were recruited. The patients' clinical characteristics were described previously (10) . Each patient was matched with a euthyroid control of similar age, sex, and body mass index (BMI). All subjects had fasting blood samples taken for the measurement of lipids, HDL subfractions, apolipoproteins, CETP, free T 4 (FT 4 ), and TSH. A second fasting blood sample was taken 15 min after 100 U/kg heparin was administered iv for the measurement of HL and lipoprotein lipase (LPL) activities. The hyperthyroid patients were started on antithyroid drug, and T 4 replacement was started in the hypothyroid patients. All parameters were measured again in the both groups of patients after 3-4 months of treatment when they had been rendered euthyroid. All subjects gave their informed consent, and the protocol was approved by the Ethics Committee of the University of Hong Kong.
Methods for measuring plasma lipids and thyroid function were described previously (10) . The normal range of FT 4 was 10 -19 pmol/L, and of TSH was 0.35-5.5 mIU/L. Serum apo A-I and apo B were measured by rate nephelometry using the Beckman Array System (Beckman Instruments, Palo Alto, CA). LpA-I was analyzed by electroimmunodiffusion using commercially available kits (Sebia, Issy les Moulineaus, France). The concentration of LpA-I:A-II was determined by the difference between total serum apo A-I and LpA-I concentrations.
HDL subfractions were isolated by density gradient ultracentrifugation as described by Kelley and Kruski (12) with minor modifications to the density gradient to improve the separation of HDL subfractions. Ultracentrifugation was carried out at 14 C, 38,000 rpm for 24 h in a Beckman SW-40 rotor. The gradient containing the separated HDL fractions was displaced upwards from the tube by infusing a dense, hydrophobic material (Maxidens, 1.9 g/mL, Sigma, CA) under the plasma layer by a constant infusion pump. The elute was passed through a ultraviolet detector and continuously monitored at 280 nm, and fractions were collected for analysis of cholesterol and protein.
Total lipolytic activity in postheparin plasma was measured using an emulsion of triolein and gum arabic as substrate (13) . HL activity was determined as the activity of the salt-resistant lipase in the presence of 1 m NaCl. LPL activity was obtained as the difference between total postheparin plasma lipase activity and HL activity (14) . Plasma CETP activity was measured as previously described (10) .
Data were tested for normality using the Wilk-Shapiro test. FT 4 level was logarithmically transformed before analyses were made because of its skewed distribution. The longitudinal analysis of each variable preand posttreatment in the patient groups was evaluated by paired t test. Associations between different parameters were determined by Pearson correlation coefficients. The statistical package RS/1 (Bolt Beranek and Newman, Cambridge, MA) was used for data analysis.
Results
The hyperthyroid patients and their controls were well matched for age (27.9 Ϯ 6.4 yr vs. 28.9 Ϯ 4.8 yr, respectively) and BMI (20. Table 1 . HDL-cholesterol was lower in the hyperthyroid patients (P Ͻ 0.01), and this was caused by a reduction in HDL 2 -C (P Ͻ 0.01), because HDL 3 -C was similar to the controls. LpA-I concentration was also lower in the hyperthyroid patients (P Ͻ 0.05) ( Table 1) . After treatment of hyperthyroidism, HDL 2 increased (P Ͻ 0.001), whereas HDL 3 decreased (P Ͻ 0.001). No marked changes were seen in LpA-I or LpA-I:A-II levels. LPL activity was similar to the controls but HL and CETP activities were both increased (P Ͻ 0.05). HL activity returned to normal (P Ͻ 0.001), but no significant change was observed in CETP activity after 4 months of treatment (Table 1) .
The age and BMI of the hypothyroid patients (39.9 Ϯ 14.6 yr, 24.7 Ϯ 4.9 kg/m 2 ) were also similar to their controls (40.4 Ϯ 15.6 yr, 24.8 Ϯ 4.5 kg/m 2 ). The median pretreatment TSH was 56.0 mIU/L (range 9.3-826.0), and FT 4 was 7.0 pmol/L (range 1.3-9.0). After T 4 replacement, TSH was 1.9 mIU/L (0.5-16.0), FT 4 was 14.0 pmol/L (10.0 -19.0), and BMI decreased (24.7 Ϯ 4.9 kg/m 2 vs. 23.8 Ϯ 4.9 kg/m 2 , P Ͻ 0.05). Before treatment, there was a trend that both HDL-C and apo A-I concentrations were higher in the hypothyroid patients than the controls, but this did not reach statistical significance. However, significant changes were seen in HDL subfractions (Table 2 ). Hypothyroid patients had higher HDL 2 -C (P Ͻ 0.05) and lower HDL 3 -C than the controls (P Ͻ 0.05). After T 4 replacement, there was a reduction mainly in HDL 2 -C (P Ͻ 0.01). Apo A-I also decreased (P Ͻ 0.05), and the changes were seen in the LpA-I particles, because the concentration of LpA-I:A-II particles remained unchanged (Table 2) . Plasma HL and CETP were lower than the controls (P Ͻ 0.05 and P Ͻ 0.01, respectively) and increased after treatment (P Ͻ 0.001 and P Ͻ 0.01, respectively). No change was seen in LPL activity.
Hyper-and hypothyroidism appeared to cause reciprocal changes in HL and CETP activities, and baseline HL and CETP activities were both related to log(FT 4 ) when data from the hyper-and hypothyroid patients were combined (HL: r ϭ 0.55, P Ͻ 0.001; CETP: r ϭ 0.63, P Ͻ 0.001). To determine whether the changes in HDL subfractions and apo A-I-containing particles were related to changes in lipase and CETP activities, correlation analyses were performed. The changes in HDL 2 -C (⌬HDL 2 -C) after treatment were related to changes in HL (⌬HL) (Fig. 1 ) and the changes in BMI (r ϭ 0.45, P Ͻ 0.01) but not with CETP or LPL. The relationship between ⌬HDL 2 -C and ⌬HL remained significant after controlling for changes in BMI (partial correlation coefficient 0.48, P Ͻ 0.01). The changes in HDL 3 -C after treatment correlated only with ⌬HL (r ϭ 0.51, P Ͻ 0.01) and not with any of the other parameters including CETP, LPL, and BMI. Changes in LpA-I (⌬LpA-I) also correlated only with ⌬HL (Fig. 2) .
Discussion
Thyroid dysfunction has a marked effect on the distribution and composition of HDL particles, and the major HDL subfraction affected appears to be HDL 2 . The present study showed that HDL 2 is reduced in hyperthyroidism and elevated in patients with hypothyroidism, and this is in keeping with the findings of previous studies (2, 8) . In addition to classifying HDL particles according to their size and density, HDL particles can also be characterised according to the apolipoprotein composition. Apo A-I and A-II are the major proteins found in HDL and form the two major HDL subclasses: those that contain only apo A-I (LpA-I) and those that contain both apo A-I and apo A-II (LpA-I:A-II). In normal subjects, the relative proportion of LpA-I is greater in HDL 2 than in HDL 3 . There is recent evidence to suggest that the protein composition of HDL significantly affects its antiatherogenic potential, and data from clinical and experimental studies suggest that LpA-I is more antiatherogenic (15) . The changes in LpA-I and LpA-I:A-II particles in thyroid disorders have not been studied previously. We showed that LpA-I concentration was lowered in hyperthyroidism and increased in hypothyroidism, whereas LpA-I:A-II concentration was unaffected. The previously well-described changes in plasma apo A-I in hyper-and hypothyroidism are mainly caused by changes in the concentration of LpA-I rather than in LpA-I:A-II particles. This is supported by the findings of O'Brien et al. (5) who reported significant changes in apo A-I concentrations after treatment of hyper-and hypothyroid patients but levels of apo A-II that remained unchanged (5) . Whether the increase in LpA-I level in hypothyroidism may partially counteract the harmful effect of raised LDL in hypothyroidism remains to be proven. Factors that influence HDL lipid composition and therefore size are known to have an important effect in modulating HDL and apo A-I metabolism. HDL particle size appears to be inversely correlated with the rate of apo A-I catabolism, with smaller HDL particles and lipid-poor apo A-I being catabolized more rapidly (16) . Because plasma lipoproteins are continuously remodeled during their transit through the plasma compartment by the actions of lipolytic enzymes and lipid transfer proteins, the activities of these proteins are important determinants of the lipid composition and size of HDL and hence its metabolism (17) . Changes in postheparin lipase and CETP activities have been described in hyper-and hypothyroidism, and this is the first study to evaluate the relative roles of these enzymes in thyroid hormone-induced changes in HDL subfractions. Because the changes in HDL subfractions after correction of the underlying thyroid disorder correlated mainly with the changes in HL activity, HL appears to be the major factor in determining HDL levels. CETP and LPL appear not to play a significant role. HL is involved in the conversion of HDL 2 to HDL 3 , and transgenic mice and rabbits that overexpress HL have markedly reduced HDL-C and apo A-I (18, 19) . Whether the changes in apo A-I observed in our study is because of changes in synthesis and/or because of changes in metabolism remains to be determined. Experimental studies have shown that apo A-I messenger RNA (mRNA) synthesis is reduced in the liver and in the intestine in hypothyroidism, and that thyroid hormone stimulates apo A-I transcription (20, 21) . However, plasma apo A-I concentration actually decreased after T 4 replacement in our hypothyroid patients. We postulate that because smaller HDL particles and lipidpoor apo-AI are known to be catabolized more rapidly (16, 19) , the changes in HL activity might indirectly affect the catabolism of apo A-I through its lipolytic effect on the lipid portion of HDL particles and hence override the effect of thyroid hormone on apo A-I mRNA synthesis.
In the present study, both HL and CETP activities correlated strongly with thyroid hormone levels, suggesting that thyroid hormone has a significant effect on the activities of these proteins, although the underlying mechanisms are not clear. Thyroid hormone regulates the transcription of certain genes. For instance thyroid hormone regulates the expression of LDL receptor at the mRNA level. Staels et al. (20) reported that HL gene expression is relatively resistant to alterations in thyroid status, but whether thyroid hormone affects posttranscriptional regulation of HL activity is not known (20) . The effect of thyroid hormone on CETP gene expression has not been studied.
In conclusion, thyroid hormone has multiple effects on lipid metabolism. In addition to its well-known effect on LDL metabolism, the present study has demonstrated that HDL metabolism is also altered in thyroid dysfunction. The effect of thyroid hormone on HDL is mediated mainly via its effect on HL activity.
